C Michael Gibson1, Roxana Mehran2, Christoph Bode3, Johnathan Halperin2, Freek Verheugt4, Peter Wildgoose5, Martin van Eickels6, Gregory Y H Lip7, Marc Cohen8, Steen Husted9, Eric Peterson10, Keith Fox11. 1. Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. Electronic address: mgibson@perfuse.org. 2. Department of Cardiology, Mount Sinai Medical Center, Mount Sinai Medical School, New York, NY. 3. Heart Center, Department for Cardiology and Angiology I, University of Freiburg, Freiburg, Germany. 4. Radboud University Medical Center, Nijmegen, the Netherlands. 5. Jansen Pharmaceuticals, Inc, Titusville, NJ. 6. Bayer Pharmaceuticals, Inc, Berlin, Germany. 7. University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, United Kingdom. 8. Division of Cardiology, Newark Beth Israel Medical Center, Newark, NJ. 9. Aarhus University Hospital, Medical Department, Hospital Unit West, Herning, Denmark. 10. Duke Clinical Research Institute, Durham, NC. 11. Centre for Cardiovascular Science, University of Edinburgh and Royal Infirmary of Edinburgh, Edinburgh, United Kingdom.
Abstract
BACKGROUND: Guidelines recommendations regarding anticoagulant therapy after percutaneous coronary intervention (PCI) among patients with atrial fibrillation (AF) rely on retrospective, nonrandomized observational data. Currently, patients are treated with triple-therapy (dual antiplatelet therapy [DAPT] + oral anticoagulation therapy), but neither the duration of DAPT nor the level of anticoagulation has been studied in a randomized fashion. Recent studies also suggest dual pathway therapy with clopidogrel plus oral anticoagulation therapy may be superior, and other studies suggest that novel oral anticoagulants such as rivaroxaban may further improve patient outcomes. DESIGN: PIONEER AF-PCI (ClinicalTrials.gov NCT01830543) is an exploratory, open-label, randomized, multicenter clinical study assessing the safety of 2 rivaroxaban treatment strategies and 1 vitamin K antagonist (VKA) treatment strategy in subjects who have paroxysmal, persistent, or permanent nonvalvular AF and have undergone PCI with stent placement. Approximately 2,100 subjects will be randomized in a 1:1:1 ratio to receive either rivaroxaban 15 mg once daily plus clopidogrel 75 mg daily for 12 months (a WOEST trial-like strategy), or rivaroxaban 2.5 mg twice daily (with stratification to a prespecified duration of DAPT 1, 6, or 12 months, an ATLAS trial-like strategy), or dose-adjusted VKA once daily (with stratification to a prespecified duration of DAPT 1, 6, or 12 months, traditional triple therapy). All patients will be followed up for 12 months for the primary composite end point of Thrombolysis in Myocardial Infarction major bleeding, bleeding requiring medical attention, and minor bleeding (collectively, clinically significant bleeding). CONCLUSION: The PIONEER AF-PCI study is the first randomized comparison of VKA vs novel oral anticoagulant therapy in patients with NVAF receiving antiplatelet therapy after PCI to assess the relative risks of bleeding complications.
RCT Entities:
BACKGROUND: Guidelines recommendations regarding anticoagulant therapy after percutaneous coronary intervention (PCI) among patients with atrial fibrillation (AF) rely on retrospective, nonrandomized observational data. Currently, patients are treated with triple-therapy (dual antiplatelet therapy [DAPT] + oral anticoagulation therapy), but neither the duration of DAPT nor the level of anticoagulation has been studied in a randomized fashion. Recent studies also suggest dual pathway therapy with clopidogrel plus oral anticoagulation therapy may be superior, and other studies suggest that novel oral anticoagulants such as rivaroxaban may further improve patient outcomes. DESIGN: PIONEER AF-PCI (ClinicalTrials.gov NCT01830543) is an exploratory, open-label, randomized, multicenter clinical study assessing the safety of 2 rivaroxaban treatment strategies and 1 vitamin K antagonist (VKA) treatment strategy in subjects who have paroxysmal, persistent, or permanent nonvalvular AF and have undergone PCI with stent placement. Approximately 2,100 subjects will be randomized in a 1:1:1 ratio to receive either rivaroxaban 15 mg once daily plus clopidogrel 75 mg daily for 12 months (a WOEST trial-like strategy), or rivaroxaban 2.5 mg twice daily (with stratification to a prespecified duration of DAPT 1, 6, or 12 months, an ATLAS trial-like strategy), or dose-adjusted VKA once daily (with stratification to a prespecified duration of DAPT 1, 6, or 12 months, traditional triple therapy). All patients will be followed up for 12 months for the primary composite end point of Thrombolysis in Myocardial Infarction major bleeding, bleeding requiring medical attention, and minor bleeding (collectively, clinically significant bleeding). CONCLUSION: The PIONEER AF-PCI study is the first randomized comparison of VKA vs novel oral anticoagulant therapy in patients with NVAF receiving antiplatelet therapy after PCI to assess the relative risks of bleeding complications.
Authors: Javier A Valle; Laura Graham; Aerin DeRussy; Kamal Itani; Mary T Hawn; Thomas M Maddox Journal: World J Surg Date: 2017-02 Impact factor: 3.352
Authors: Gerald Chi; Megan K Yee; Arzu Kalayci; Mathieu Kerneis; Fahad AlKhalfan; Roxana Mehran; Christoph Bode; Jonathan L Halperin; Freek W A Verheugt; Peter Wildgoose; Martin van Eickels; Gregory Y H Lip; Marc Cohen; Eric D Peterson; Keith A A Fox; C Michael Gibson Journal: J Thromb Thrombolysis Date: 2018-10 Impact factor: 2.300
Authors: Javier A Valle; Susan Shetterly; Thomas M Maddox; P Michael Ho; Steven M Bradley; Amneet Sandhu; David Magid; Thomas T Tsai Journal: Circ Cardiovasc Interv Date: 2016-06 Impact factor: 6.546
Authors: Matthew W Sherwood; Derek D Cyr; W Schuyler Jones; Richard C Becker; Scott D Berkowitz; Jeffrey B Washam; Günter Breithardt; Keith A A Fox; Jonathan L Halperin; Graeme J Hankey; Daniel E Singer; Jonathan P Piccini; Christopher C Nessel; Kenneth W Mahaffey; Manesh R Patel Journal: JACC Cardiovasc Interv Date: 2016-08-22 Impact factor: 11.195
Authors: Christoph B Olivier; Patrick Weik; Melanie Meyer; Susanne Weber; Philipp Diehl; Christoph Bode; Martin Moser; Qian Zhou Journal: J Thromb Thrombolysis Date: 2016-08 Impact factor: 2.300
Authors: Alexander C Fanaroff; Vic Hasselblad; Matthew T Roe; Deepak L Bhatt; Stefan K James; Ph Gabriel Steg; C Michael Gibson; E Magnus Ohman Journal: Int J Cardiol Date: 2017-03-14 Impact factor: 4.164